Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
Would you re-challenge a patient with Rituximab who responded well in terms of their RA but developed symptomatic tachycardia after their first infusion?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Are there any recommendations for restarting JAKi after a provoked DVT?
How do you approach dyspnea in a patient with seropositive rheumatoid arthritis with normal imaging findings but abnormal PFT findings (restriction, reduced DLCO)?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
How do you approach choosing between subcutaneous and IV actemra for RA?